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Introduction: Procalcitonin (PCT) biomarker is suggested to tailor antibiotic therapy in the medical intensive care
unit (ICU) but studies in perioperative medicine are scarce. The aim of this study was to determine whether PCT
reported thresholds are associated with the initial treatment response in perioperative septic shock secondary to
intra-abdominal infection.
Methods: This single ICU, observational study included patients with perioperative septic shocks secondary to
intra-abdominal infection. Demographics, PCT at days 0, 1, 3, 5, treatment response and outcome were collected.
Treatment failure included death related to the initial infection, second source control treatment or a new onset
intra-abdominal infection. The primary endpoint was to assess whether PCT thresholds (0.5 ng/ml or a drop from
the peak of at least 80%) predict the initial treatment response.
Results: We included 101 consecutive cases. Initial treatment failed in 36 patients with a subsequent mortality of
75%. Upon admission, PCT was doubled when treatment ultimately failed (21.7 ng/ml ± 38.7 vs. 41.7 ng/ml ± 75.7;
P = 0.04). Although 95% of the patients in whom PCT dropped down below 0.5 ng/ml responded to treatment, 50%
of the patients in whom PCT remained above 0.5 ng/ml also responded successfully to treatment. Moreover, despite
a PCT drop of at least 80%, 40% of patients had treatment failure.
Conclusions: In perioperative intra-abdominal infections with shock, PCT decrease to 0.5 ng/ml lacked sensitivity to
predict treatment response and its decrease of at least 80% from its peak failed to accurately predict treatment response.
Studies in perioperative severe infections are needed before using PCT to tailor antibiotic use in this population.Introduction
Overuse of antibiotics is common in both medical and
surgical (perioperative medicine) intensive care units (ICU)
leading to the development of antimicrobial resistance
and hospital-acquired infections [1]. To decrease hospital-
acquired infection incidence, antimicrobial consumption
reduction in the surgical ICU is needed but unfortunately
controlled studies comparing two different durations of* Correspondence: s-jaber@chu-montpellier.fr
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reproduction in any medium, provided the orantibiotics are scarce [2]. So, strategies other than random-
ized controlled studies might be of interest [3,4]. Recently,
new strategies to reduce antibiotic duration have included
the development of biomarker-directed treatment algo-
rithms [5,6]. Procalcitonin (PCT), the 116-amino acid pre-
cursor of calcitonin, is elevated consecutively in several
systemic inflammatory conditions and its magnitude corre-
lates well with injury severity and prognosis [7,8]. In the
ICU, serial PCT measurement might be used as a surro-
gate to facilitate the early discontinuation of antimicrobials
[5,9]. Indeed, it has been reported that using a PCT plasma
threshold from 0.25 ng/ml to 0.50 ng/ml or its decrease of
at least 80% compared to its peak [5,9-11] allows withhold-
ing antibiotics earlier without affecting clinical outcome
[12-15]. Surprisingly, most of the studies that evaluated the
interest of PCT to guide antimicrobial duration includedd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the most habitual reasons to admit a patient in a periopera-
tive situation to the surgical ICU. To the best of our know-
ledge, few studies focused on PCT in peritonitis, with its
very heterogeneous severity criteria [11,16,17].
As a first step to evaluate PCT as a tool to discontinue
antibiotics, the aim of the present study was to assess
whether the PCT thresholds of 0.5 ng/ml or its drop
from the peak of at least 80%, previously reported in
medical patients, could predict the response to initial
treatment in surgical patients admitted for an intra-
abdominal infection with septic shock. Our hypothesis is
that the PCT kinetic may be associated with the patient’s
response to the initial treatment.
Material and methods
Study setting and patients
This observational study was performed in an adult ICU
of a university hospital from April 2008 to February
2011. Retrospective analysis was performed on data pro-
spectively acquired from an electronic chart review that
automatically records all physiological and biological data.
Because of its observational, non-interventional design, the
present study was approved by the local ethics committee
(Comité d’Organisation et de Gestion de l’Anesthésie
Réanimation du Centre Hospitalier Universitaire de
Montpellier (COGAR)) and, in accordance with French
law, informed consent was waived.
All consecutive patients (18 years or older) who were
admitted to the ICU with abdominal septic shock or who
developed septic shock consecutive to an intra-abdominal
infection while hospitalized in the ICU were screened. In
our ICU, it is part of our routine care to measure PCT
levels upon ICU admission and subsequently every 48 to
72 h in case of septic shock. Patients discharged or dead
before 48 h and those in whom PCT was not monitored
for logistical reasons were not analyzed further. Patients
admitted with acute pancreatitis were excluded because
PCT is increased in acute pancreatitis, whatever the pres-
ence of an infectious complication [18].
Definitions
Septic shock was defined by evidence of infection and a
systemic response to infection, in addition to a systolic
blood pressure of <90 mmHg, despite adequate fluid
replacement, and a need for vasopressors for at least
1 hour, according to the American College of Chest
Physicians/Society of Critical Care Medicine Consensus
Conference Committee criteria [19]. Intra-abdominal in-
fection was defined as an intra-abdominal septic focus re-
quiring surgical treatment with proof of infection in the
succeeding laparotomy or a documented intra-abdominal
infection [20]. Successful treatment was defined by either
an uneventful recovery (no further invasive proceduresnecessary) after the first line of treatment including inva-
sive intervention or the absence of an intra-abdominal
infectious focus at the time of relaparotomy if judged
necessary [20-24]. As reported by other studies focus-
ing on PCT [8] and/or peritonitis treatment response
[11,16,21], treatment failure was defined by either death
because of the initial infectious focus or a relaparotomy
or radiological drainage showing the persistence of an
ongoing intra-abdominal infection or a new onset intra-
abdominal infection. We thus divided patients into a
group with a successful initial treatment (treatment success
group) and a group in which the initial treatment failed
(treatment failure group).
Treatment strategy
In all cases that needed surgery, peritoneal fluid was
sampled for microbiology. After abundant peritoneal lav-
age, stomies were preferred to primary anastomosis but
the attending surgeon in charge of the case made the final
decision. Relaparotomy was exclusively performed on de-
mand and not scheduled systematically. The patients re-
ceived antibiotic therapy prior to anesthesia according to
the Infectious Diseases Society of America (IDSA) guide-
lines [20]. For intra-abdominal infection with septic shock,
we used piperacillin-tazobactam, amikacin and antifungal
treatment when yeasts were positive on direct peritoneal
fluid examination. The antibiotic therapy was continued
until resolution of clinical signs of infection and recovery
of gastrointestinal function according to the IDSA guide-
lines, but recommendation was made not to exceed 15
days if the patient’s condition improved [20].
Baseline assessment and data collection
The following data were recorded upon ICU admission:
demographic characteristics, microbiology on blood cul-
tures, peritoneal and biliary tract samples, severity of
underlying medical condition stratified according to the
criteria of McCabe and Jackson, simplified acute physi-
ology score II (SAPS II) [25], Sepsis-related Organ Failure
Assessment (SOFA) score [26], the presence of co-
morbidities, and reason for admission to the ICU. Micro-
biology data was also recorded. During the ICU stay, we
collected the SOFA score at days 0, 1, 3 and 5 and the
outcome including the need for relaparotomy, invasive
procedure to complete the septic focus eradication, noso-
comial infection occurrence, length of ICU stay, duration
of mechanical ventilation and survival at ICU discharge.
Septic focus cure was evaluated as defined above.
Biomarkers: PCT and C-reactive protein (CRP) assays
For all patients, serum was collected for CRP and PCT
assays upon admission (day 0) and subsequently at days
1, 3 and 5. For PCT, we used the previously published
methodology [27]. Briefly, the biochemistry laboratory used
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technology on a Kryptor analyzer (Brahms Diagnostica,
Berlin, Germany). The Kryptor analyzer detection limit
in 100 μl of serum was 0.019 ng/ml and sensitivity
(interassay variation coefficient, 20%) was 0.06 ng/ml. The
95th percentile reference was 0.064 ng/ml.
Endpoint
The primary endpoint was to assess whether most com-
monly reported PCT thresholds used to discontinue the
antibiotics in the critically ill (either 0.5 ng/ml or the
drop from its peak of at least 80%) could predict the re-
sponse to the initial treatment (success vs. failure) in
perioperative intra-abdominal infection with shock.
The secondary endpoints were the evaluation of the
relation between the PCT kinetic and other markers
(temperature, CRP and SOFA) kinetics with response
to treatment.
Statistical analysis
Data are expressed as mean ± SD or SEM for normally
distributed data, and median with interquartile range
(IQR) for non-normally distributed data. Continuous vari-
ables were compared using Student’s t test for normally
distributed variables and the Mann-Whitney rank-sum
test for non-normally distributed variables. The chi-square
test or the Fisher exact test was used to compare categor-
ical variables. Because the kinetic of biomarkers was more
evaluated than their absolute values in the present study,
we used a mixed logistic regression model taking into ac-
count both time (as repeated measures were performed
and analyzed) and biomarkers in the comparison model.
Biomarker and time were considered as fixed effects and
outcome (success vs. treatment failure) was considered asFirst line of treatment 
success 
n=65
Intra-abdominal infection and Septic sh
n=114
Patients meeting the inclusion 
criteria n=101









Figure 1 Flow chart of the study.the dependent variable. Comparisons were performed be-
tween day 0 and day 5. Missing biomarker data were nei-
ther deleted nor replaced or imputed as missing data are
handled by the mixed logistic regression [28]. Sensibility,
specificity, positive and negative predictive values as well
as accuracy for both thresholds (PCT decrease below
0.5 ng/ml or drop from its peak of at least 80%) were also
calculated. Statistical analysis was performed by an inde-
pendent statistician (NM), with R software (version 2.10.1).
Significance was established at P <0.05.
Results
During the study period, among the 1,692 patients ad-
mitted to our ICU, 101 consecutive patients meeting the
inclusion criteria were included (Figure 1). Patients who
were discharged within two days after ICU admission
were not analyzed further (Figure 1). Patients’ demo-
graphics are presented in Table 1. Surgical procedure
was necessary in 87% of the patients and all were treated
with vasopressors and mechanical ventilation within the
first 24 hours of ICU stay. Microbiology culture is pre-
sented in Table 2. No differences were noted according
to the treatment response. Initial treatment failed in 36
patients (Table 3). The main cause of failure was relapar-
otomy or radiological drainage for additional source
control in 17 cases (47%) or death related to the initial
infection in 14 cases (39%). Four patients in the treatment
success group needed a relaparotomy or a radiological
drainage for hematoma (n = 2) or a superinfection suspi-
cion (n = 2) but no infection was diagnosed by this second
look. Antibiotic spectrum modification because of treat-
ment failure or nosocomial infection occurred in 14
patients in the treatment failure group (39%) vs. 5 in
the treatment success group (8%), P = 0.003. At day 28,Patients not meeting the 
inclusion criteria 
n=1578
Length of stay in the ICU 
less than 2 days 
n=13
ock







Table 1 Characteristics of the study population
All Treatment success Treatment failure P
(n = 101) (n = 65) (n = 36)
Age (years), 66 ± 15 66 ± 16 66 ± 12 0.60
Male 60 (60) 40 (62) 20 (56) 0.71
Body mass index (kg/m2) 27.1 ± 7.5 26.2 ± 5.2 28.2 ± 10.3 0.14
SAPS II upon ICU admission 49 ± 17 46 ± 15 56 ± 17 0.006
SOFA upon ICU admission 9.7 ± 3.2 9.0 ± 2.6 11.1 ± 3.3 0.0003
Respiratory 1.8 ± 1.0 1.6 ± 1.0 2.2 ± 0.9 <0.01
Hemodynamic 4.0 ± 0 4.0 ± 0 4.0 ± 0 >0.99
Neurologic 1.8 ± 0.9 1.8 ± 0.9 2.1 ± 1.0 0.09
Liver 0.8 ± 1.1 0.6 ± 0.8 1.1 ± 1.4 0.08
Hematology 0.6 ± 0.9 0.5 ± 0.9 0.7 ± 0.8 0.05
Kidney 1.0 ± 1.1 0.8 ± 1.0 1.3 ± 1.1 0.04
Past medical history
Hypertension 45 (45) 27 (42) 18 (50) 0.84
Coronary artery disease 20 (20) 13 (20) 7 (19) 0.94
NYHA III-IV heart insufficiency 14 (14) 8 (12) 6 (17) 0.56
COPD 13 (13) 8 (12) 5 (14) 0.82
Diabetes mellitus 21 (21) 14 (22) 7 (19) 0.80
Cancer 40 (40) 26 (40) 14 (39) 0.82
Cirrhosis 12 (12) 7 (11) 5 (14) 0.64
Site of septic focus
Distal esophagus/stomach 14 (14) 8 (12) 6 (17) 0.54
Biliary tract 20 (20) 13 (20) 7 (19) 0.95
Small intestine 26 (26) 18 (28) 8 (22) 0.54
Colorectal 36 (36) 25 (38) 11 (31) 0.43
Spontaneous peritonitis 2 (2) 0 2 (6) 0.06
Other 3 (3) 1 (2) 2 (6) 0.25
Surgical procedure performed 87 (87) 58 (89) 29 (81) 0.23
Categorical data are expressed as number and percentage. Continuous data are expressed as mean and standard deviation or median and quartiles. Comparisons were
made between patients in whom the first-line treatment succeeded and patients in whom the first-line treatment failed. COPD, chronic obstructive pulmonary disease;
ICU, intensive care unit; NYHA, New York Heart Association; SAPS II, severity acute physiology score II [23]: SOFA, sequential organ failure assessment [24].






(n = 134) (n = 89) (n = 45)
E. coli 35 (26) 21 (24) 14 (31) 0.35
Enterobacter sp 11 (8) 7 (8) 4 (9) 0.83
P. aeruginosa 8 (8) 6 (7) 2 (4) 0.96
E. faecalis 12 (12) 7 (8) 5 (11) 0.54
E. faecium 13 (9) 8 (9) 5 (11) 0.69
Other Enterobacteriaceae 17 (13) 14 (16) 3 (7) 0.14
Candida sp 11 (11) 7 (8) 4 (9) 0.84
Anaerobes 8 (6) 3 (4) 5 (11) 0.07
Others 19 (14) 16 (18) 3 (7) 0.07
Categorical data are expressed as number and percentage.
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mortality (Table 3).
Upon ICU admission, PCT in patients with subsequent
failure of initial treatment was double than in those with
successful initial treatment, P = 0.04. We assessed whether
the PCT thresholds of either 0.5 ng/ml or its relative drop
of at least 80% from the peak could predict the treatment
response. Among the 101 patients, six patients (five in the
success and one in the failure group) had less than three
PCT measurements for logistical reasons and could there-
fore not be analyzed adequately. Almost 50% of cases
responded successfully to treatment even if PCT concen-
tration was constantly above 0.5 ng/ml during the ICU stay
(Figure 2A). A decrease of at least 80% compared to the
peak was not associated with treatment success (Figure 2B).
Table 3 Outcome characteristics of the 101 patients according to the initial treatment response
All Treatment success Treatment failure P
(n = 101) (n = 65) (n = 36)
Relaparotomy needed 21 (21) 3 (5) 18 (50) <0.001
Surgical drainage after first line treatment 8 (8) 1 (1) 7 (19) 0.001
Duration of antibiotic treatment during ICU stay (days) 11.7 ± 7.2 11.3 ± 6.1 12.9 ± 8.8 0.84
Nosocomial infection 36 (36) 15 (23) 21 (58) <0.001
Cytomegalovirus reactivation 5 (5) 2 (3) 3 (8) 0.24
Duration of mechanical ventilation (days) 8 ± 6 6 ± 7 9 ± 9 0.002
ICU length of stay (days) 11 ± 10 10 ± 9 14 ± 11 0.08
Mortality in the ICU 29 (29) 2 (3) 27 (75) <0.001
Cause of death
Refractory shock related to initial infection 5 (5) 0 5 (14) <0.001
Secondary surgical complication 7 (7) 0 7 (19) <0.001
Nosocomial infection as the main cause of death 4 (11) 0 4 (11) <0.001
Other including intensive care withdrawal 13 (13) 2 (3) 11 (31) <0.001
Continuous data are expressed as mean and standard deviation. Categorical data are expressed as number and percentage. ICU, intensive care unit.
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equal to or greater than 80% of its peak, 95% did respond
successfully to treatment. Interestingly, when PCT de-
crease remained superior to 0.5 ng/ml and above 80% of
its peak, almost 50% of the patients also responded suc-
cessfully to the initial treatment (Figure 2C). Using the
threshold of 0.5 ng/ml, PCT predicted the treatment suc-
cess with a sensitivity of 48%, specificity of 94%, positive
predictive value of 94%, negative predictive value of 52%
and accuracy of 65%. Using a drop equal to or greater than
80% of the peak, PCT predicted the treatment success with
a sensitivity of 63%, specificity of 43%, positive predictive
value of 66%, negative predictive value of 41% and accuracy
of 56%. Among the 35 patients admitted for a post-
operative intra-abdominal infections, we found similar per-
formance values for PCT without significant differences
compared to patients admitted for community-acquired
intra-abdominal infection.
However, when the PCT kinetic between admission
and day 5 was considered, it was not significantly differ-
ent according to treatment response (Figure 3).
We then examined the relation between temperature,
CRP and SOFA kinetics and the treatment response. Nei-
ther temperature nor CRP drops between admission and
day 5 were different according to the patient’s response
to treatment (Figure 3A and 3B). Interestingly, SOFA
score drop was superior in patients who responded suc-
cessfully to the treatment compared to patients who did
not (P <0.001) (Figure 3D).
Discussion
The present study reports that neither PCT threshold of
0.5 ng/ml nor its decrease of at least 80% from its peakvalue could accurately predict the treatment response in
a subpopulation of intra-abdominal cases with septic
shock. Although 95% of patients in whom PCT decreased
below 0.5 ng/ml responded successfully to treatment,
50% of the patients in whom PCT remained superior to
0.5 ng/ml also responded positively to the treatment mak-
ing this threshold of 0.5 ng/ml a specific but not a sensi-
tive biomarker. Decrease of at least 80% from the peak
was not associated with treatment response. In periopera-
tive medicine, PCT may be used to tailor antibiotic therapy
using either an absolute cutoff (for example 0.5 ng/ml) or a
significant drop compared to the peak value (for example
80%) [12]. In the present study, we examined whether
those thresholds were associated with initial treatment re-
sponse in perioperative critically ill patients admitted for
an intra-abdominal infection with shock.
PCT was initially used as a diagnostic biomarker.
However, high interindividual differences, failure of
a single measurement to accurately identify infection
[27,29] and false positive cases have been reported [30].
Recent meta-analyses and reviews concluded that PCT
cannot reliably differentiate infectious from noninfec-
tious causes of inflammation in critically ill patients [30].
Moreover, PCT threshold to differentiate bacterial infec-
tion vs. inflammation is commonly higher in periopera-
tive medicine than in medical patients [31]. Another way
to consider PCT interest in critically ill patients is to use
it as a guide to discontinue the antibiotic therapy earlier.
Studies that focused on PCT as a tool to withdraw the
antibiotics earlier used both an absolute value of PCT
(from 2 to 0.25 ng/ml) and a significant drop from the
peak value (either a significant reduction of 25 to 35% in
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Number of evaluated patients 
PCT remained higher than 
0.5 ng/ml
PCT decreased more
than 80% of its peak
PCT decreased less
than 80% of its peak
PCT decreased more than 80%
of its peak AND
to 0.5 ng/ml or below
PCT decreased less than 80%
of its peak AND remained
higher than 0.5 ng/ml
Figure 2 Treatment response according to procalcitonin drop. (A) Percentage of treatment success according to the lowest PCT value from
ICU admission to day 5. Patients were dichotomized according to whether the lowest PCT value was inferior to 0.5 ng/ml or not. Among the 31
patients in whom PCT decreased below the threshold of 0.5 ng/ml, 29 responded successfully to the treatment. Thirty-one patients among 64
did also respond successfully to treatment although PCT remained superior to 0.5 ng/ml. (B) Percentage of treatment success according to PCT
decrease from its peak value from ICU admission to day 5. Patients were dichotomized according to whether the PCT value decreased by more
than 80% of the peak value or not. Among the 58 patients in whom PCT decreased by at least 80% from its peak, 38 responded successfully to
the treatment. Twenty-two patients among 37 did also respond successfully to treatment although PCT drop was lower than 80% of the peak.
(C) Percentage of treatment success according the lowest PCT value and the PCT decrease from its peak value from ICU admission to day 5
(combination of (A) and (B)). Among the 20 patients in whom PCT both decreased by at least of 80% from its peak and below 0.5 ng/ml,
19 responded successfully to the treatment. Twelve patients among 26 did also respond successfully to treatment although PCT drop was
lower than 80% of its peak and its absolute value remained superior to 0.5 ng/ml. On the x-axis is presented the number of patients in
whom the treatment was successful of the number of patients analyzed. Six patients could not be analyzed because of logistical reasons.
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Figure 3 Treatment response according to temperature, C-reactive protein, serum procalcitonin and SOFA score kinetics. Kinetics of
temperature (A), C-reactive protein (B), serum procalcitonin (C) and Sepsis-related Organ Failure Assessment (SOFA) score (D) in patients according to
the initial treatment response from day 0 to day 5. Comparisons were made to assess whether the biomarkers kinetic and not their absolute values are
different according to the initial treatment impact between day 0 and day 5. Results are expressed as means ± standard error for the mean (SEM). On
the x-axis is presented the number of patients in whom data were available.
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ied, as recently suggested [9,12] whether an absolute drop
down to at least 0.5 ng/ml or a significant reduction
of at least 80% compared to the peak value was associ-
ated with the success of the initial treatment for septic
shock related to an intra-abdominal infection. We re-
ported that a PCT threshold of 0.5 ng/ml was specific
but neither sensitive nor accurate and that a PCT de-
crease of at least 80% from its peak was not associated
with the patient’s response to treatment (Figures 2, 3).
Duration of antibiotics in this subpopulation could not
be recommended based on PCT level whatever the
threshold used.
This finding contrasts with studies on ventilator-
associated pneumonia prognosis [8] and with the main
study that focused on the PCT kinetic as a prognostic
biomarker in nonselected critically ill patients. However,
those studies focused on pneumonia or on medical pa-
tients, including less than 20% of patients needing sur-
gery although higher PCT ranges might be observed in
surgical patients [31].Studies focusing on the PCT static threshold value (for
example 0.5 ng/ml) to predict the patient’s outcome in
severe intra-abdominal infections are sparse. In a study
combining 246 cases of sepsis, severe sepsis or septic
shock secondary to peritonitis, PCT was associated with
patient’s survival in the ICU [17]. Conversely, another
study reported that PCT of 16 ng/ml discriminated sur-
vivors vs. nonsurvivors with a positive predictive value
of only 30% in secondary peritonitis [16]. To the best of
our knowledge, the present study is the first to focus on
a homogenous group with all patients presenting septic
shock related to an intra-abdominal infection. We report
that, upon admission, the PCT absolute value might be
an indicator of treatment failure (Figure 3) but a PCT
decrease of at least 80% from the peak or its kinetic
from admission to day 5 could not accurately predict
treatment response (Figure 2B). One study reported that
PCT but not APACHE II day 2/day 1 ratio was associ-
ated with the treatment response in a case mix with
an unknown ratio of shock [21]. Another single center
study prospectively included 37 patients (including 21
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[33]. The authors reported that the PCT kinetic between
day 0 and day 5 was not better than the SOFA kinetic to
predict ICU mortality. We focused on initial treatment
response rather than on mortality but our results are con-
sistent with that study, highlighting that organ failure
score (SOFA score in the present study) might be as
helpful as other biomarkers to assess response to treat-
ment in critically ill patients.
The present study has some limits. First, it is a single-
center observational study. Second, to distinguish treat-
ment failure from treatment success, we considered that
failure of treatment could be either deaths related to
infection or infectious surgical complications. Although
it may appear cumbersome to cumulate death with other
complications, these criteria have been extensively used
in studies on antibiotic evaluation. Patients with a length
of stay in the ICU of less than two days were not ana-
lyzed to avoid fulminant septic shock. Third, we did not
perform receiver operating characteristic curves as the
aim of the present study was to assess whether published
thresholds could be used in intra-abdominal infection
with shock rather than to determine new thresholds
in another population of interest. Finally, PCT could
remain persistently above 0.5 ng/ml because of other
reasons than abdominal infection but treatment re-
sponse was assessed based solely on the abdominal in-
fection course.Conclusions
In this cohort of 101 perioperative cases with septic
shock consecutive to an intra abdominal infection, we
report that, PCT threshold of 0.5 ng/ml or its decrease
of at least 80% from its peak are not accurate markers to
predict patient’s response to the initial treatment. Before
using PCT to discontinue antibiotic therapy in surgical
patients, further studies evaluating specifically PCT in
surgical septic shock are needed.Key messages
 Procalcitonin decrease below 0.5 ng/ml was specific
but neither sensitive nor accurate to predict
treatment response in 101 septic shock patients
secondary to an intra abdominal infection
 Procalcitonin decrease of at least 80% from its peak
failed to accurately predict treatment response in
this populationAbbreviations
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